ArticleAntimicrobial agents and chemotherapy2011
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria.Malaria journal · 2017Pooled it
- Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review.Malaria journal · 2014Pooled it
- Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial.The Lancet. Microbe · 2022Trial
- Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon.Malaria journal · 2012Trial
- Mapping the global distribution and spread of theVirus evolution · 2026Article
- Metagenomic complexity of high, seasonal transmission of Plasmodium spp. in asymptomatic carriers in Northern Sahelian Ghana.Communications medicine · 2025Article
- Ex Vivo Drug Susceptibility ofPathogens (Basel, Switzerland) · 2025Article
- Metagenomic analysis reveals extreme complexity ofmedRxiv : the preprint server for health sciences · 2025Article
- Diagnostic performance of a 5-plex malaria immunoassay in regions co-endemic for Plasmodium falciparum, P. vivax, P. knowlesi, P. malariae and P. ovale.Scientific reports · 2022Article
- The Role of Autophagy in the Innate Immune Response to Fungal Keratitis Caused by Aspergillus fumigatus Infection.Investigative ophthalmology & visual science · 2020Article
- Characterization of Plasmodium infections among inhabitants of rural areas in Gabon.Scientific reports · 2019Article
- Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study.PLoS neglected tropical diseases · 2015Article
- Recrudescence of Plasmodium malariae after Quinine.Case reports in medicine · 2014Article
- Acute respiratory distress syndrome and acute renal failure from Plasmodium ovale infection with fatal outcome.Malaria journal · 2013Article
- Current challenges in travelers' malaria.Current infectious disease reports · 2013Article
- Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.Trends in parasitology · 2012Review
- Management of imported malaria in Europe.Malaria journal · 2012Review
- Cytoadherence and severe malaria.The Malaysian journal of medical sciences : MJMS · 2012Article
- An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.PLoS neglected tropical diseases · 2012Article
- Epidemiology of malaria in endemic areas.Mediterranean journal of hematology and infectious diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 4 countries.
Funding
Abstract
Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P. malariae and P. ovale. In order to assess this, in vivo and in vitro efficacy studies were conducted in patients with monoinfection in Papua, Indonesia. Consecutive patients with uncomplicated malaria due to P. ovale or P. malariae were enrolled in a prospective clinical trial, provided with supervised chloroquine treatment, and followed for 28 days. Blood from patients with P. malariae or P. ovale parasitemia greater than 1,000 per microliter underwent in vitro antimalarial drug susceptibility testing using a modified schizont maturation assay. Of the 57 evaluable patients in the clinical study (P. malariae, n = 46; P. ovale, n = 11), none had recurrence with the same species during follow-up. The mean parasite reduction ratio at 48 h was 86 (95% confidence interval [CI], 57 to 114) for P. malariae and 150 (95% CI, 54 to 245) for P. ovale (P = 0.18). One patient infected with P. malariae, with 93% of parasites at the trophozoite stage, was still parasitemic on day 4. In vitro drug susceptibility assays were carried out successfully for 40 isolates (34 infected with P. malariae and 6 with P. ovale). The P. malariae infections at trophozoite stages had significantly higher chloroquine 50% effective concentrations (EC(50)s) (median, 127.9 nM [range, 7.9 to 2,980]) than those initially exposed at the ring stage (median, 14.0 nM [range, 3.5 to 27.0]; P = 0.01). The EC(50) for chloroquine in P. ovale was also higher in an isolate initially at the trophozoite stage (23.2 nM) than in the three isolates predominantly at ring stage (7.8 nM). Chloroquine retains adequate efficacy against P. ovale and P. malariae, but its marked stage specificity of action may account for reports of delayed parasite clearance times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.